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Fluorizoline is a prohibitin-binding compound that triggers apoptosis in several cell lines from murine and human origin, as well as
in primary cells from hematologic malignancies by inducing the integrated stress response and ER stress. Recently, it was described
that PHB (Prohibitin) 1 and 2 are crucial mitophagy receptors involved in mediating the autophagic degradation of mitochondria.
We measured mitophagy in HeLa cells expressing Parkin and in A549, a lung cancer cell line that can undergo mitophagy in a
Parkin-independent manner, and we demonstrated that both fluorizoline and rocaglamide A, another PHB-binding molecule,
inhibit CCCP- and OA-induced mitophagy. Moreover, we demonstrated that PHBs are mediating Parkin-dependent mitophagy. In
conclusion, besides being a potent pro-apoptotic compound, we present fluorizoline as a promising new mitophagy modulator
that could be used as anticancer agent.
Oncogenesis           (2021) 10:64 ; https://doi.org/10.1038/s41389-021-00352-9
INTRODUCTION
Mitochondria are crucial for multiple intracellular processes. These
organelles are responsible for the generation of ATP through
oxidative phosphorylation (OXPHOS) but they also control the
intracellular calcium levels, regulate the innate immune response
and control the cell death through the initiation of the intrinsic
apoptotic pathway [1]. Thus, the selective removal of damaged or
dysfunctional mitochondrial is crucial to maintain a proper cell
homeostasis [2]. Mitophagy is the form of macroautophagy that
ensures the elimination of damaged mitochondria by the
lysosomes to maintain the integrity of the mitochondrial pool
[3]. Diverse stimuli, including nutrient starvation, higher mito-
chondrial respiration activity, hypoxia, respiratory chain inhibitors,
or iron deficiency can promote mitophagy as a protective
mechanism against mitochondrial stress [4].
The best-described mitophagy pathway is driven by PINK1
(PTEN induced putative kinase 1) and Parkin, a RBR (RING-
Between-RING) E3 ubiquitin (Ub) ligase. Under basal conditions,
mitochondrial transmembrane potential allows the import and
processing of PINK1 in the mitochondrial matrix by the protease
PARL (Presenilins-associated rhomboid-like protein), leading to its
constant degradation. Upon mitochondrial depolarization, PARL
cannot longer process PINK1, which leads to its dimerization and
autophosphorylation. Once activated and stabilized in the outer
mitochondrial membrane (OMM), PINK1 enhances the activation
and recruitment of Parkin, which results in the polyubiquitination
of numerous OMM proteins that are recognized by the autophagy
cargo adaptor p62 and OPTN [5].
Although the PINK1/Parkin signaling pathway is the mechanism
of mitophagy most studied and well-characterized, other E3 Ub
ligases, such as ARIH1, MUL1, SIAH1 SMURF1, and GP78, have
been described to cooperate with, or act alternatively, to Parkin
activity downstream of PINK1 [6, 7]. Furthermore, mitophagy can
also be mediated by Ub-independent receptor pathways. Several
mitochondrial membrane proteins (e.g., PHB2, FUNDC1, BNIP3,
NIX, BCL2L13, and FKBP8) and lipids (e.g., cardiolipin and
ceramides) can act as mitophagy receptors [8].
Fluorizoline is a fluorinated thiazoline pro-apoptotic compound
that induces apoptosis, in a p53-independent manner, in a wide
range of cancer cell lines [9]. Moreover, fluorizoline also showed
high apoptotic capacity in acute myeloid leukemia [10], chronic
lymphocytic leukemia [11], and multiple myeloma [12] primary
cancer cells. Fluorizoline directly binds and targets Prohibitin (PHB)
1 and 2 [9, 13], evolutionary conserved and ubiquitously
expressed proteins, mainly localized in the inner mitochondrial
membrane (IMM), where they interact with each other to form a
macromolecular structure [14]. These PHB heteromeric ring-like
complexes in the IMM participate in numerous processes in the
mitochondria, including protein-quality control, OXPHOS chain
synthesis and assembly, ROS formation or mitochondrial DNA
organization [14, 15]. In addition, PHB2 was discovered as a novel
mitophagy receptor involved in targeting mitochondria for
autophagic degradation in mammals [16].
It was described that upon mitochondrial depolarization, PHB2
or PHB2/PHB1 complex directly binds to autophagosome-
associated protein LC3 [16]. Furthermore, recently it was further
described that upon mitochondrial depolarization, PHB2 binds to
PARL, releasing PGAM5 in the process [17], which is responsible
for retaining and stabilizing PINK1 on the OMM to initiate
mitophagy [18]. Also, it was reported that PHB2 is required for
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cholestasis-induced mitophagy, where PHB2 brings LC3 to the
damaged mitochondria by interacting with p62 and LC3 [19].
The impact of mitophagy on the cellular fate is controversial
as the clearance of mitochondria can have diverse effects on
tumor development, growth, and progression. Mitophagy can
facilitate survival through the adaptation to stress by removing
mitochondria that could potentially be permeabilized to induce
cell death or, conversely, it can induce cell death due to the
excessive removal of mitochondria [20]. On one hand, genetic
inhibition of mitophagy pathways sensitizes cancer cells to
apoptosis in response to anticancer treatments, supporting the
pro-survival role of mitophagy in cancer cells [2]. In fact,
enhanced mitophagy contributes to cisplatin and etoposide
resistance in cancer cells [21, 22], while mitophagy impairment
resensitizes drug-resistant cancer cells [22, 23]. On the other
hand, dysfunctional mitochondria and increased mitochondrial
ROS can promote tumorigenesis, cancer progression, metasta-
sis, and drug resistance through DNA, lipid, and protein
oxidation [2].
Nevertheless, there are several studies suggesting that mito-
phagy inhibitors in combination with conventional cancer
treatment can markedly improve the effectiveness of chemother-
apy [24]. For that reason, in this study, we investigated whether
fluorizoline can modulate mitophagy by targeting PHBs.
MATERIAL AND METHODS
Cell culture
HeLa and A549 were supplied by the European Collection of Cell Culture
(ECACC). Cells were cultured in Dulbecco’s Modified Eagle Medium (DMEM)
supplemented with 10% fetal bovine serum, 100 U/mL penicillin, and
100 ng/mL streptomycin. Cells were cultured at 37 °C in a humidified
atmosphere containing 5% carbon dioxide. Cell cultures were periodically
tested for mycoplasma contamination by PCR.
Mito-mKeima mitophagy analysis
HeLa and A549 cells were infected with mito-mKeima (m-Keima)
expressing lentiviral vector. The fluorescence profile of this biomarker is
pH-dependent, making it a perfect biosensor of mitochondrial degradation
by the lysosomes [25]. Excitation at 488 nm and emission at >620 nm was
used to detect m-Keima in mitochondria in the cytosol and excitation at
561 nm and emission at >620 nm was used to detect mitochondria in
lysosomes (Supplementary Fig. 1A). m-Keima was analyzed by flow
cytometry using MACSQuant VYB and MACSQuant software (Miltenyi
Biotec, Bergisch Gladbach, Germany).
To calculate the percentage of mitophagy positive cells, 10,000 single
events were acquired for each sample and subsequently gated the cells
experiencing a shift to acidic m-Keima (Supplementary Fig. 1B).
Short hairpin RNA
To generate the inducible PHB2 knockdown in HeLa and A549 cells,
lentiviral particles were generated by transfecting HEK 293T cells with the
Tet-pLKO-puro vector from Addgene (Watertown, Massachusetts, USA)
containing the PHB2 short hairpin sequence 5′-GACAGAGAGGGCCAAGG
ACCTCGAGGTCCTTGGCCCTCTCTGTC-3′ under doxycycline promoter.
Furtherly, HeLa and A549 cells were infected with these viral particles
and selected with 2 μg/mL puromycin.
Reagents
The synthesis of fluorizoline was performed as previously described [9]. Q-
VD-OPh and bafilomycin A were from R&D systems (Minneapolis,
Minnesota, USA). CCCP, Oligomycin, and Antimycin A were obtained from
Sigma-Aldrich (St Louis, MO, USA). Rocaglamide A was purchased from
Enzo Life Sciences (Farmingdale, New York, USA).
Cell viability
Cell viability was measured by measuring phosphatidylserine exposure by
annexin V staining and analyzed by flow cytometry using FACSCantoTM
and FACSDivaTM software (Becton Dickinson, NJ, USA). Cell viability was
expressed as the percentage of annexin V-negative population, which
corresponds to the nonapoptotic cells. Cells were incubated with annexin
binding buffer and annexin V for 15min in the dark before analysis.
Western blot
Whole-cell protein extracts were obtained by lysing cells with Laemmli
sample buffer. Protein concentration was measured with the Micro BCA
Protein Assay Reagent kit (Pierce, Rockford, Illinois, USA). 20–40 µg of
protein extracts were subjected to reducing conditions, loaded onto a
polyacrylamide gel, and then transferred to Immobilon-P membranes from
Millipore (Billerica, Massachusetts, USA). One hour after blocking the
nonspecific binding sites with 5% (w/v) non-fat milk in Tris-buffered saline
with Tween® 20, membranes were incubated overnight at 4 °C with the
following specific primary antibodies: β-actin (AC-15, Sigma-Aldrich), PHB1
(sc-28259, Santa Cruz, Dallas, TX, USA), PHB2/REA (07–234, Millipore),
VDAC1 (sc-8828, Santa Cruz), HSP60 (4870 S, Cell Signaling, Danvers, MA,
USA), GRP75 (sc-13967, Santa Cruz), MTCO2 (ab110258, Abcam, Cam-
bridge, UK), PINK1 (6946, Cell Signaling). Antibody binding was detected
using a secondary antibody conjugated to horseradish peroxidase, and the
enhanced chemiluminescence detection system (Amersham, Little Chal-
font, UK). Quantification of band intensities was conducted using Multi
Gauge V3.0 software (FujiFilm Corporation). The relative density of each
protein and condition was referred to the internal normalization control.
Immunostaining
Cells were grown on coverslips before treatment. Cells were washed in
PBS, fixed with 4% paraformaldehyde in PBS for 20min, permeabilized
with 0.1% TritonX-100 in PBS for 3 min, and blocked in 2% BSA in PBS for
30min. Primary antibodies -TOM20 (sc-17764, Santa Cruz), PHB2
(ab182139, abcam), LC3 (14600–1-AP, Proteintech, Manchester, UK)- were
used at 1:200 overnight at 4 °C, followed by secondary antibodies at 1:1000
and DAPI (0.5 µg/ml) for 1 h at room temperature. Anti-mouse Alexa Fluor
488 and anti-rabbit Alexa Fluor 647 were obtained from Molecular Probes
(Invitrogen, Carlsbad, CA, USA). Cells were mounted with Fluoromount G
(SouthernBiotech, Birmingham, AL, USA). Images were acquired with a Carl
Zeiss model LSM880 confocal microscope and a Apochromat 63×/1.4 Oil
M27 objective lens and they were collected using 405, 488, and 561 nm
laser lines for excitation and appropriate emission filters. Images were
analyzed with Image J Software. Pearson’s coefficient was obtained with
JACoP plugin [26].
Quantitative RT-PCR
Total DNA was isolated from HeLa cells using the ‘Blood & cell culture DNA
mini kit’ from QIAGEN (Hilden, Germany) according to the manufacturer’s
protocol. The relative DNA expression levels of APP and COX II were
obtained by real-time quantitative PCR, using with SYBR green on the ABI
Prism 7900 HT Fast Real-Time PCR System. APP (F: 5′-TTTTTGTGTGCTCTC
CCAGGTCT-3′, R: 5′-TGGTCACTGGTTGGTTGGC-3′) and COX II (F: 5′-
CGTCTGAACTATCCTGCCCG-3, R: 5′-TGGTAAGGGAGGGATCGTTG-3′). PCR
data were captured and analyzed using the Sequence Detector software
(SDS version 2.2.2; Applied Biosystems).
Statistical analysis
The results are shown as the mean ± standard error of the mean (SEM) of
values obtained in three or more independent experiments. Statistical
analysis was performed using the Student’s t-test (two-tailed) or ANOVA-
Tukey by using GraphPad Prism 6.0c Software Inc (San Diego, CA, USA).
Differences were considered significant at p values below 0.05 (*p < 0.05;
**p < 0.01; ***p < 0.001).
RESULTS
Fluorizoline inhibits mitophagy in cancer cells overexpressing
Parkin
To study the effect of fluorizoline in Parkin-mediated mitophagy
we performed the experiments in HeLa cells stably expressing
Parkin. In order to measure mitophagy, the cells stably expressed
mito-mKeima fluorophore, a biosensor of mitochondrial degrada-
tion by the lysosomes [27]. This cellular marker changes its
fluorescence profile depending on the pH, which allows the
measurement of m-Keima fluorescence excitation conversion
from green (488 nm-cytosolic) to red (561 nm-mitochondrial)
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using fluorescence-activated cell sorting (FACS) [25] (Supplemen-
tary Fig. 1).
We treated HeLa Parkin cells for 16 h with 10 μM protonophore
carbonyl cyanide m-chlorophenyl hydrazone (CCCP) or a combi-
nation of 1 μM oligomycin and 1 μM antimycin A (OA), to
depolarize the mitochondria and induce mitophagy. The results
showed that the addition of 5 or 10 μM fluorizoline can block
CCCP and OA-induced mitophagy (Fig. 1A). Strikingly, even the
lower dose of fluorizoline that does not induce a pronounced cell
death can inhibit the mitophagy outcome (Fig. 1B).
Next, we studied the co-localization of LC3 and the mitochon-
drial marker TOM20 in HeLa Parkin cells upon mitophagy induction
by 1 μM OA, in the presence or absence of 10 μM fluorizoline. Cells
were treated with 20 μM Q-VD-OPh, a caspase inhibitor to avoid
the appearance of apoptotic bodies, and with 40 nM bafilomycin A,
an inhibitor of the autophagosome-lysosome fusion that facilitates
Fig. 1 Fluorizoline inhibits mitophagy in cancer cells overexpressing Parkin. HeLa cells overexpressing Parkin (CT) were treated for 16 h
with 10 μM CCCP or 1 μM oligomycin/1 μM antimycin A (OA) in the absence (UT) or presence of 5 or 10 μM fluorizoline (F) (A, B). HeLa Parkin
cells treated with 20 μM pan-caspase inhibitor Q-VD-OPh and 40 nM bafilomycin (CT) were treated for 8 h with 1 μM oligomycin/1 μM
antimycin (OA), in the absence (UT) or presence of 10 μM fluorizoline (F). Cells were co-immunostained for DAPI (blue), TOM20 (green), and
LC3 (red) and co-localization was analyzed by confocal microscopy. White arrows indicate the mitochondrial marker within the
autophagosome. These are representative images of three independent experiments (C). The co-localization between LC3 and TOM20 was
measured and is represented as the Pearson’s coefficient (n= 3) (D). HeLa cells overexpressing Parkin (CT) were treated for 16 h with 10 μM
CCCP or 1 μM oligomycin/1 μM antimycin A (OA), in the absence (UT) or presence of 500 nM rocaglamide A (RocA) (E, F). m-Keima was
measured by flow cytometry and it is expressed as the mean ± SEM (n= 5 independent experiments) of the percentage of mitophagy positive
cells (A, E). Viability was measured by flow cytometry and it is expressed as the mean ± SEM (n= 4 independent experiments) of the
percentage of non-apoptotic cells (annexin V-negative) (B, F). ###p < 0.001 CT versus CCCP and OA-treated cells and **p < 0.01 and ***p < 0.001
UT versus F or RocA-treated cells.
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the accumulation of LC3-II in the cells. We checked that the
addition of Q-VD-OPh did not modulate the effects of fluorizoline
in the mitophagy process (Supplementary Fig. 2). Upon 8 h of
mitophagy induction, we can observe a significant increase in the
co-localization of LC3 with TOM20 (Fig. 1C, D). However, when
fluorizoline is present this co-localization is lost, demonstrating its
inhibitory role in the process.
In parallel, we decided to check whether other PHB binding
molecules could also block mitophagy induction; thus, we tested
the natural PHB-binding compound rocaglamide A [28]. Measur-
ing the conversion of m-Keima, we observed that 500 nM
rocaglamide A is able to block CCCP and OA-induced mitophagy
(Fig. 1E). Similar to fluorizoline treatment, rocaglamide A was able
to inhibit mitophagy in a dose that does not induce high levels of
apoptosis (Fig. 1F).
Fluorizoline inhibits the removal of damaged mitochondria
To further characterize the ability of fluorizoline to prevent
mitophagy we monitored the removal of damaged mitochondria
by measuring the disappearance of mitochondrial markers.
First, we performed an immunofluorescence staining against
the mitochondrial proteins TOM20 and PHB2 in HeLa Parkin cells
treated with 20 μM Q-VD-OPh. The loss of mitochondria in HeLa
Parkin cells upon 1 μM OA treatment was clearly observed as the
signal of TOM20 and PHB2 significantly disappeared (Fig. 2A). On
the contrary, the addition of 10 μM fluorizoline during OA
treatment significantly prevented the loss of TOM20 and
PHB2 staining (Fig. 2B and Supplementary Fig. 3). Similar
protective effects were observed with 500 nM rocaglamide A
(Fig. 2A, B and Supplementary Fig. 3).
Then, we proceed to measure the disappearance of TOM20 and
PHB2 by immunoblot, alongside several others mitochondrial
markers, such as GRP75, VDAC1, MTCO2, and PHB1. HeLa Parkin
cells were treated for 16 h with 10 μM CCCP or 1 μM OA while
treated with 10 μM fluorizoline or 500 nM rocaglamide A. We
could confirm that both PHB binding compounds block the
degradation of mitochondrial proteins induced by CCCP and OA
(Fig. 2C, D). The specificity of these proteins to monitor mitophagy
was confirmed when HeLa cells lacking Parkin were treated for
16 h with CCCP and OA and did not experience any modulations
of these proteins (data not shown).
Next, we measured the removal of damaged mitochondria by
measuring the degradation of mitochondrial DNA upon treatment.
We chose COX II and amyloid precursor protein (APP) genes as
indicatives of mitochondrial and nuclear DNA, respectively [29]. As
expected, 10 μM fluorizoline treatment prevented the degradation
of mitochondrial DNA induced by 1 μM OA (Fig. 2E), in a similar
way that 500 nM rocaglamide A did (Fig. 2F).
Therefore, by measuring the disappearance of mitochondrial
proteins and DNA, we can conclude that both PHB binding
compounds, fluorizoline and rocaglamide A, inhibit the removal of
damaged mitochondria in cancer cells.
Fluorizoline inhibits Parkin-independent mitophagy
Next, we studied whether fluorizoline could inhibit Parkin-
independent mitophagy. We decided to use A549 lung carcinoma
cells, in which mitophagy depends on the endogenous expres-
sion of the E3 ligase ARIH1 and does not express Parkin [21]. A549
cells were treated for 24 h with 10 μM CCCP or 1 μM OA in the
presence or absence of 5 μM or 10 μM fluorizoline and we
measured m-Keima shift. Indeed, the results showed that
fluorizoline was also able to inhibit the mitophagy process in
this cell line (Fig. 3A).
In addition, compared to HeLa cells, we observed that A549
cells were less sensitive to fluorizoline-induced apoptosis at the
same doses (Fig. 3B), but they exhibit similar levels of mitophagy
inhibition, which confirms that the inhibition observed is not a
consequence of the pro-apoptotic effects of fluorizoline.
Fluorizoline prevents PINK1 stabilization in the OMM
Recently, it was reported that upon mitochondrial depolarization,
PHB2 binds to PARL instead of interacting with PGAM5, therefore
allowing PGAM5 to stabilize PINK1 in the OMM, to recruit Parkin,
and to initiate the mitophagy process [17]. Therefore, we studied
whether fluorizoline treatment decreases PINK1 protein levels.
Fluorizoline prevented the accumulation of PINK1 in HeLa
Parkin cells induced by a 16 h treatment of 10 μM CCCP and 1 μM
OA, accompanied by a stabilization of TOM20 and PHB2 protein
levels (Fig. 4A). To confirm that fluorizoline was inhibiting
mitophagy initial steps, we checked for PINK1 protein levels after
a shorter treatment of CCCP and OA. We were able to observe
PINK1 protein stabilization with CCCP and OA in HeLa Parkin cells
(Fig. 4B, C) and with OA in A549 cells (Fig. 4D, E) after 6 h of
treatment. In both cases, PINK1 protein accumulation was
inhibited by 10 μM fluorizoline and 500 nM rocaglamide A. As
this process takes place at the beginning of the mitophagy
process, TOM20 protein levels still remain stable (Fig. 4B). Thus, we
confirmed both fluorizoline and rocaglamide A prevent
PINK1 stabilization in the OMM upon mitochondria depolarization.
Effect of PHB depletion in Parkin-dependent and
-independent mitophagy
To further study the role of PHBs in the inhibition of mitophagy by
fluorizoline, we infected HeLa Parkin cells with a short hairpin RNA
(shRNA) against PHB2 under the control of an inducible promoter
regulated by doxycycline. Upon 72 h treatment with 200 ng/mL
doxycycline, the induction of shPHB2 decreased the expression of
PHB2 and PHB1 (Fig. 5A, C), as both PHBs are interdependent at
the protein level [30, 31]. PHB depleted cells, when treated with
10 μM CCCP and 1 μM OA, were unable to undergo mitophagy,
similarly to when cells were treated with 10 μM fluorizoline (Fig.
5B). Moreover, the absence of PHBs had a similar effect than
fluorizoline treatment when monitoring the removal of damaged
mitochondria, as the levels of GRP75, VDAC1, and TOM20
remained stable upon CCCP and OA treatment (Fig. 5A, C).
Since most studies proving PHB2 involvement in mitophagy
were reported in cells undergoing mitophagy in a Parkin-
dependent manner, and considering that we had demonstrated
that fluorizoline could also block Parkin-independent mitophagy,
we wanted to check whether PHB2 was also essential to mediate
mitophagy in A549 cells. shPHB2 A549 cells were treated for 24 h
with 1 μM OA, after a previous 72 h treatment with 200 ng/mL
doxycycline to delete PHBs (Fig. 5D, E), and m-Keima measure-
ment showed that A549 lacking PHBs could undergo mitophagy
(Fig. 5F). Furthermore, both 10 μM fluorizoline and 500 nM
rocaglamide A were able to inhibit OA-induced mitophagy in
PHB-depleted A549 cells at the same level than in control cells.
DISCUSSION
In this manuscript, we described that the PHB-binding compound
fluorizoline can inhibit Parkin-dependent and -independent
mitophagy. Moreover, while the presence of PHB is essential to
undergo mitophagy in HeLa cells overexpressing Parkin, A549
cells appear to have alternative mechanisms to induce mitophagy,
independently of PHB. Therefore, although fluorizoline was first
thought to be inhibiting mitophagy by binding to PHB, the
possibility of fluorizoline having other targets is left open. Despite
this, we do not fully discard the possibility that PHB2 is in some
level involved in the mitophagy process in A549. Rocaglamide A
has already been described to inhibit mitophagy by targeting
PHBs [17] and, although it is possible, it is very unlikely that
fluorizoline and rocaglamide A share another target besides PHB
that is also involved in mitophagy. Thus, the role of PHB in Parkin-
independent mitophagy should be further analyzed.
Since it was first described by Levine and colleagues that PHB2
is an IMM mitophagy receptor that binds to LC3 upon
S. Núñez-Vázquez et al.
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mitochondrial depolarization [16], several studies have focused on
the implication of PHB2 in this process. Recently, it was described
that PHB2 promotes PINK1 stabilization in the OMM through the
PARL-PGAM5-PINK1 axis [17]. In this study, they also tested the
flavagline PHB ligands, FL3 and rocaglamide A, and they observed
that those compounds inhibit PINK1/Parkin-mediated mitophagy.
Both compounds were able to inhibit the elimination of
mitochondria and the recruitment of Parkin and PINK1 at the
OMM, at the same time that their treatment caused an increase in
PARL protein levels. Based on this work, fluorizoline would prevent
the PGAM5 proteolytic protection conferred by PHB and therefore,
PARL would constantly process PGAM5, not allowing the
stabilization of PINK1.
There are some contradictions in the literature about the role of
PHB2 ligands regarding mitophagy. Although rocaglamide A
enhances natural killer cell-mediated lysis through inhibition of
autophagy [32], another study showed that rocaglamide A can
also act as a mitophagy inducer in pancreatic cancer cells [33]. This
cell type-dependent role of PHB2 ligands in mitophagy could be
related to the dual role of mitophagy in cell death and survival.
Mitophagy and, more generally, autophagy is a pro-survival
stress response; however, prolonged over-activation of the
Fig. 2 Fluorizoline inhibits the removal of damaged mitochondria. HeLa Parkin cells (CT) were treated with 20 μM pan-caspase inhibitor Q-
VD-OPh (A, B, E, F) or not (C, D) while treated for 16 h with 1 μM oligomycin/1 μM antimycin (OA) or 10 μM CCCP, in the absence (UT) or
presence of 10 μM fluorizoline (F) or 500 nM rocaglamide A (RocA). Cells were co-immunostained for DAPI (blue), TOM20 (green), and PHB2
(red) and co-localization was analyzed by confocal microscopy (A). The integrated density of TOM20 and PHB2 was quantified. Mean ± SEM
(n= 3 independent experiments) (B). Protein levels from whole-cell lysates were analyzed by western blot and actin was used as a loading
control (C). TOM20 and VDAC1 protein expression levels were quantified. Mean ± SEM (n= 3 independent experiments) (D). The genes for
COX II and the amyloid precursor protein (APP) were amplified and measured by RT-qPCR as indicatives of mitochondrial and nuclear DNA,
respectively. Mean ± SEM (n= 3 independent experiments) (E, F). These are representative images of three independent experiments (A, C).
**p < 0.01 and ***p < 0.001 CT versus OA-treated cells (B); *p < 0.05, **p < 0.01 UT versus F or RocA-treated cells (D−F); ##p < 0.01 CT versus
CCCP and OA-treated cells (D).
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autophagosomal/lysosomal pathway can lead to autophagic cell
death [34]. A similar threshold is present to define the cellular
outcome during the ISR and ER stress [35], both processes
involved in the mechanism of fluorizoline-induced apoptosis [36].
While the stress response of these signaling pathways is pro-
apoptotic in HeLa and HAP1 cells [36], it has a pro-survival role in
HEK293T and U2OS cells [37]. Therefore, we hypothesize that the
response to the ISR upon fluorizoline treatment might be
coordinated with the inhibition or induction of mitophagy as a
global adaptive response to prevent or to promote fluorizoline-
induced apoptosis. In this hypothesis, the pro-apoptotic induction
of the ISR by fluorizoline in HeLa cells would be accompanied by
an inhibition of mitophagy, while the pro-survival activation of ISR
in HEK293T would be linked to an induction of mitophagy to
prevent the apoptotic outcome of fluorizoline treatment.
Supporting this idea, it was demonstrated that inhibition of
autophagy enhances ER stress-induced cisplatin cytotoxicity in
HeLa cells [38]. Furthermore, mitophagy induction has been
associated with drug resistance and the inhibition of autophagy
can sensitize tumor cells to the cytotoxicity of anticancer drugs
[39]. In addition, the UPR derived from ER stress can induce
mitophagy to clear stress-damaged mitochondria [40].
This opens the possibility to use fluorizoline in combination
with other chemotherapeutic treatments to avoid future resis-
tances or to avoid ER stress pro-survival effects of anticancer
drugs. There are several studies suggesting that mitophagy
Fig. 3 Fluorizoline inhibits Parkin-independent mitophagy. A549 cells (CT) were treated for 24 h with 10 μM CCCP or 1 μM oligomycin/1 μM
antimycin A (OA) in the absence (UT) or presence of 5 or 10 μM fluorizoline (F). m-Keima was measured by flow cytometry and it is expressed
as the mean ± SEM (n= 5 independent experiments) of the percentage of mitophagy positive cells (A). Viability was measured by flow
cytometry and it is expressed as the mean ± SEM (n= 5 independent experiments) of the percentage of non-apoptotic cells (annexin
V-negative) (B). ###p < 0.001 CT versus CCCP and OA-treated cells; **p < 0.01 and ***p < 0.001 UT versus F-treated cells.
Fig. 4 Fluorizoline prevents PINK1 stabilization in the OMM. HeLa Parkin cells (CT) were treated for 16 h with 10 μM CCCP or 1 μM
oligomycin/1 μM antimycin A (OA) in the absence (UT) or presence of 10 μM fluorizoline (F) (A). HeLa Parkin (B, C) and A549 (D, E) cells were
treated for 6 h with or without 10 μM CCCP or 1 μM oligomycin/1 μM antimycin A (OA) in the absence (UT) or presence of 10 μM fluorizoline (F)
or 500 nM rocaglamide A (RocA). Protein levels from whole-cell lysates were analyzed by western blot and actin was used as loading control.
These are representative images of three independent experiments (A, B, D). PINK1 protein expression levels were quantified. Mean ± SEM
(n= 3 independent experiments) (C, E). *p < 0.05, **p < 0.01, ***p < 0.001 UT versus F or RocA-treated cells; #p < 0.05, ###p < 0.001 CT versus
CCCP and OA-treated cells.
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inhibitors in combination with conventional cancer treatment can
markedly improve the effectiveness of chemotherapy [23, 41, 42].
However, it seems that both mitophagy inducers and inhibitors
may be effective in anti-cancer therapy [20]. For instance,
dihydroergotamine was shown to induce cell death in A549 cells
by inducing mitophagy [43]. Also, mitochondrial fragmentation
caused by the anti-cancer drug phenanthroline promotes
mitophagy [44]. Moreover, mitophagy stimulated by low-
intensity ultrasound therapy in the presence of curcumin induces
cell death in nasopharyngeal carcinoma cells [45]. On the contrary,
the inhibition of mitophagy can also represent an effective
strategy for therapy, as it has been demonstrated that it might
enhance the cell death induced by several anticancer drugs. For
instance, Drp1-GTPase MDIVI-1 inhibits mitophagy by disrupting
the mitochondrial fragmentation process, which helps to over-
come tumor cell resistance to cisplatin treatment [23]. Also, the
mitophagy inhibitor liensinin sensitizes triple-negative human
breast cancer cells to doxorubicin treatment [46].
Taken together, this study showed that pro-apoptotic PHB-
binding compound fluorizoline can block the process of
mitophagy in cancer cells. Furthermore, it also exposed the need
to further analyze the role of mitophagy receptor PHB2 in
Fig. 5 Effect of PHB depletion in Parkin-dependent and -independent mitophagy. HeLa Parkin shPHB2 cells (CT) were treated for 16 h with
10 μM CCCP or 1 μM oligomycin/1 μM antimycin A (OA) in the absence (UT) or presence of 10 μM fluorizoline (F), or after a 72 h 200 ng/mL
doxycycline (Dox) treatment (A, C). HeLa Parkin shPHB2 cells (CT) were treated with 200 ng/mL doxycycline for 72 h and then treated with
10 μM CCCP or 1 μM oligomycin/1 μM antimycin A (OA) for 16 h (B). A549 shPHB2 cells (CT), previously treated or not with 200 ng/mL
doxycycline (Dox) for 72 h, were treated with 1 μM oligomycin/1 μM antimycin A (OA) for 24 h in the absence (UT) or presence of 10 μM
fluorizoline (F) or 500 nM rocaglamide A (RocA) (D, F). Protein levels from whole-cell lysates were analyzed by western blot and actin was used
as a loading control. These are representative images of three independent experiments (A, D). m-Keima was measured by flow cytometry and
referenced to their corresponding untreated controls and it is expressed as the mean ± SEM (n= 3 independent experiments) of the
percentage of mitophagy positive cells (B, F). PHB2, TOM20, and VDAC1 protein expression levels were quantified. Mean ± SEM (n= 3
independent experiments) (C, E). ***p < 0.001 Dox-treated versus Dox-non treated cells (B); *p < 0.05, **p < 0.01, ***p < 0.001 CT versus CCCP
and OA-treated cells (C, E).
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Parkin-independent mitophagy. In conclusion, besides a potent
pro-apoptotic compound, we present fluorizoline as a promising
new mitophagy modulator as an anticancer agent.
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